Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.
Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Passardi A, et al. Among authors: ragazzini a. Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9. Sci Rep. 2017. PMID: 28874797 Free PMC article. Clinical Trial.
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Frassineti GL, Amadori D. Passardi A, et al. Among authors: ragazzini a. Ann Oncol. 2015 Jun;26(6):1201-1207. doi: 10.1093/annonc/mdv130. Epub 2015 Mar 3. Ann Oncol. 2015. PMID: 25735317 Free article. Clinical Trial.
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.
Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, Rosetti P, Bravaccini S, Calistri D, Saragoni L, Casadei Gardini A, Ragazzini A, Frassineti GL, Amadori D, Passardi A. Ulivi P, et al. Among authors: ragazzini a. J Transl Med. 2012 May 8;10:87. doi: 10.1186/1479-5876-10-87. J Transl Med. 2012. PMID: 22569004 Free PMC article.
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).
Casadei Gardini A, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S, Scarpi E, Passardi A, Zoli W, Ragazzini A, Amadori D, Frassineti GL. Casadei Gardini A, et al. Among authors: ragazzini a. PLoS One. 2014 Mar 18;9(3):e92071. doi: 10.1371/journal.pone.0092071. eCollection 2014. PLoS One. 2014. PMID: 24642661 Free PMC article.
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A, Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A. Amadori M, et al. Among authors: ragazzini a. Eur Radiol. 2018 Jul;28(7):2969-2978. doi: 10.1007/s00330-017-5254-5. Epub 2018 Feb 7. Eur Radiol. 2018. PMID: 29417252
Hemangioblastoma of the gastrointestinal tract: a first case.
Casadei Gardini A, Pieri F, Fusaroli P, Oboldi D, Passardi A, Monti M, Rosetti P, Calpona S, Valgiusti M, Ragazzini A, Amadori D, Frassineti GL. Casadei Gardini A, et al. Among authors: ragazzini a. Int J Surg Pathol. 2013 Apr;21(2):192-6. doi: 10.1177/1066896912475082. Int J Surg Pathol. 2013. PMID: 23516170 Free article.
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C. Ulivi P, et al. Among authors: ragazzini a. Int J Mol Sci. 2014 Dec 31;16(1):747-57. doi: 10.3390/ijms16010747. Int J Mol Sci. 2014. PMID: 25561229 Free PMC article.
22 results